A.P. Pharma, Inc. (NASDAQ: APPA) 52.6% LOWER; today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for APF530 in the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting. APF530 is a long-acting formulation of granisetron utilizing the Company’s proprietary Biochronomer™ drug delivery system. A conference call has been scheduled for Friday, March 19, 2010 at 9:00 a.m. Eastern Time.

Palm (NASDAQ: PALM) 19.5% LOWER; reports Q3 adj-loss of $0.61, versus the analyst estimate of ($0.42). Revenue for the quarter was $366 million, which compares